IL286209A - A solid formulation of a capsid composition modulator - Google Patents

A solid formulation of a capsid composition modulator

Info

Publication number
IL286209A
IL286209A IL286209A IL28620921A IL286209A IL 286209 A IL286209 A IL 286209A IL 286209 A IL286209 A IL 286209A IL 28620921 A IL28620921 A IL 28620921A IL 286209 A IL286209 A IL 286209A
Authority
IL
Israel
Prior art keywords
solid formulation
capsid assembly
assembly modulator
modulator
capsid
Prior art date
Application number
IL286209A
Other languages
English (en)
Hebrew (he)
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/352,754 external-priority patent/US10973801B2/en
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of IL286209A publication Critical patent/IL286209A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL286209A 2019-03-13 2021-09-09 A solid formulation of a capsid composition modulator IL286209A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP2019056348 2019-03-13
US16/352,754 US10973801B2 (en) 2018-03-14 2019-03-13 Capsid assembly modulator dosing regimen
PCT/IB2019/000231 WO2019175657A1 (fr) 2018-03-14 2019-03-13 Schéma posologique de modulateur d'assemblage de capside
EP19197566 2019-09-16
PCT/EP2020/056991 WO2020183020A1 (fr) 2019-03-13 2020-03-13 Formulation solide de modulateur d'assemblage de capside

Publications (1)

Publication Number Publication Date
IL286209A true IL286209A (en) 2021-10-31

Family

ID=72427202

Family Applications (1)

Application Number Title Priority Date Filing Date
IL286209A IL286209A (en) 2019-03-13 2021-09-09 A solid formulation of a capsid composition modulator

Country Status (16)

Country Link
EP (1) EP3937928A1 (fr)
JP (1) JP2022524819A (fr)
KR (1) KR20210137484A (fr)
CN (1) CN113557016A (fr)
AU (1) AU2020235442A1 (fr)
BR (1) BR112021017525A2 (fr)
CA (1) CA3132095A1 (fr)
CR (1) CR20210481A (fr)
EC (1) ECSP21067052A (fr)
IL (1) IL286209A (fr)
JO (1) JOP20210250A1 (fr)
MA (1) MA55280A (fr)
MX (1) MX2021011030A (fr)
PE (1) PE20212107A1 (fr)
SG (1) SG11202109710QA (fr)
WO (1) WO2020183020A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017181141A2 (fr) 2016-04-15 2017-10-19 Novira Therapeutics, Inc. Associations et méthodes comprenant un inhibiteur d'ensemble capside
SG11202007097QA (en) * 2018-03-14 2020-08-28 Janssen Sciences Ireland Unlimited Co Capsid assembly modulator dosing regimen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202126620A (zh) 2013-05-17 2021-07-16 愛爾蘭商健生科學愛爾蘭無限公司 胺磺醯基吡咯醯胺衍生物及其作為用於治療b型肝炎藥物的用途
SG11202007097QA (en) * 2018-03-14 2020-08-28 Janssen Sciences Ireland Unlimited Co Capsid assembly modulator dosing regimen

Also Published As

Publication number Publication date
MA55280A (fr) 2022-01-19
JP2022524819A (ja) 2022-05-10
KR20210137484A (ko) 2021-11-17
SG11202109710QA (en) 2021-10-28
CA3132095A1 (fr) 2020-09-17
PE20212107A1 (es) 2021-11-04
BR112021017525A2 (pt) 2021-11-23
EP3937928A1 (fr) 2022-01-19
AU2020235442A1 (en) 2021-08-12
CR20210481A (es) 2021-10-25
CN113557016A (zh) 2021-10-26
ECSP21067052A (es) 2021-11-18
JOP20210250A1 (ar) 2023-01-30
MX2021011030A (es) 2021-10-13
WO2020183020A1 (fr) 2020-09-17

Similar Documents

Publication Publication Date Title
IL292156A (en) Transduced azacils as trmp8 modulators
IL279242A (en) Modulators of the hepatitis B capsid assembly
HUE061394T2 (hu) TMEM16A modulátorok
GB2576056B (en) Modulators
GB201813855D0 (en) Modulator assembly
EP3886820B8 (fr) Formulations de capsules
IL277262A (en) Dosing regimen for capsid composition modulator
GB201915094D0 (en) New formulations
IL290356A (en) Formulations for Resotide
GB201904338D0 (en) Fluorouracil-containing formulations
GB2585587B (en) Modulators
IL284691A (en) formulations
GB2589428B (en) Linearized modulator
SG11202008431UA (en) Catalyst formulations
GB201910092D0 (en) New formulations
GB201918974D0 (en) Gpr52 modulator compounds
GB201918992D0 (en) GPR52 modulator compounds
GB201916298D0 (en) GPR52 modulator compounds
HK40073308A (en) Gpr52 modulator compounds
GB201903889D0 (en) PDE5 modulator formulations
HK40037496B (en) Hepatitis b capsid assembly modulators
GB202003998D0 (en) PED5 modulator formulations
GB201911063D0 (en) Formulations
GB201910093D0 (en) New formulations
GB201905105D0 (en) Formulations